Michael Gelband’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-31,830
| Closed | -$4.51M | – | 1904 |
|
|
2025
Q4 | $4.51M | Sell |
31,830
-602
| -2% | -$87.2K | 0.04% | 505 |
|
|
2025
Q3 | $4.55M | Sell |
32,432
-40,167
| -55% | -$5.44M | 0.05% | 446 |
|
|
2025
Q2 | $9.13M | Buy |
72,599
+70,185
| +2,907% | +$8.05M | 0.08% | 253 |
|
|
2025
Q1 | $267K | Sell |
2,414
-13,430
| -85% | -$1.7M | ﹤0.01% | 1250 |
|
|
2024
Q4 | $2.16M | Buy |
+15,844
| New | +$1.96M | 0.01% | 687 |
|
|
2024
Q3 | – | Sell |
-13,304
| Closed | -$1.83M | – | 1932 |
|
|
2024
Q2 | $1.83M | Sell |
13,304
-24,050
| -64% | -$3.3M | 0.01% | 814 |
|
|
2024
Q1 | $5.15M | Sell |
37,354
-8,710
| -19% | -$1.19M | 0.04% | 376 |
|
|
2023
Q4 | $6.07M | Buy |
46,064
+14,276
| +45% | +$1.64M | 0.04% | 304 |
|
|
2023
Q3 | $3.58M | Sell |
31,788
-84,917
| -73% | -$8.94M | 0.03% | 463 |
|
|
2023
Q2 | $11M | Sell |
116,705
-57,295
| -33% | -$5.6M | 0.09% | 231 |
|
|
2023
Q1 | $17.6M | Buy |
174,000
+100,994
| +138% | +$10.5M | 0.15% | 141 |
|
|
2022
Q4 | $8.72M | Buy |
73,006
+22,025
| +43% | +$2.58M | 0.13% | 203 |
|
|
2022
Q3 | $5.42M | Sell |
50,981
-12,207
| -19% | -$1.24M | 0.07% | 374 |
|
|
2022
Q2 | $6.16M | Buy |
63,188
+16,066
| +34% | +$1.48M | 0.08% | 337 |
|
|
2022
Q1 | $4.42M | Sell |
47,122
-19,618
| -29% | -$1.66M | 0.06% | 434 |
|
|
2021
Q4 | $5.68M | Buy |
66,740
+40,867
| +158% | +$3.76M | 0.06% | 389 |
|
|
2021
Q3 | $2.48M | Sell |
25,873
-29,521
| -53% | -$2.79M | 0.03% | 642 |
|
|
2021
Q2 | $5.39M | Buy |
+55,394
| New | +$5.31M | 0.06% | 327 |
|
|
2021
Q1 | – | Sell |
-6,983
| Closed | -$669K | – | 2432 |
|
|
2020
Q4 | $669K | Sell |
6,983
-11,840
| -63% | -$1.14M | 0.01% | 1073 |
|
|
2020
Q3 | $1.81M | Sell |
18,823
-7,353
| -28% | -$851K | 0.04% | 442 |
|
|
2020
Q2 | $3.19M | Sell |
26,176
-2,913
| -10% | -$322K | 0.08% | 275 |
|
|
2020
Q1 | $2.52M | Buy |
+29,089
| New | +$2.85M | 0.14% | 148 |
|
|
2019
Q4 | – | Sell |
-44,746
| Closed | -$4.03M | – | 1755 |
|
|
2019
Q3 | $4.03M | Buy |
44,746
+6,907
| +18% | +$645K | 0.14% | 135 |
|
|
2019
Q2 | $3.19M | Sell |
37,839
-14,219
| -27% | -$1.17M | 0.13% | 108 |
|
|
2019
Q1 | $4.59M | Buy |
52,058
+37,225
| +251% | +$3.11M | 0.34% | 53 |
|
|
2018
Q4 | $1.06M | Buy |
+14,833
| New | +$1.42M | 0.07% | 86 |
|
Other funds holding NBIX
Michael Gelband's NBIX Position: Q1 2026 in Review
Michael Gelband sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 31,830 shares — an estimated $4.51M sold.
Michael Gelband first reported a position in NBIX in Q4 2018 and held it in 26 quarters. The position peaked at $17.6M in Q1 2023. 697 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Michael Gelband reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
- Michael Gelband sold 31,830 Neurocrine Biosciences shares in Q1 2026, an estimated $4.51M.
- Michael Gelband first reported a position in Neurocrine Biosciences in Q4 2018 and held it in 26 quarters.
- Michael Gelband's Neurocrine Biosciences position peaked at $17.6M in Q1 2023.
- 697 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.